EcoDrugPlus

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSPPRG00000011866
Gene Symbol: HTR2A
4 Cross references
218 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSPPRG00000005499
Gene Symbol: HTR2B
3 Cross references
204 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSPPRG00000000141
Gene Symbol: HTR2C
4 Cross references
223 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSPPRG00000002141
Gene Symbol: HTR3A
3 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSPPRG00000020122
Gene Symbol: HTR3B
3 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 3d

Ensembl ID : ENSPPRG00000007564
Gene Symbol: HTR3D
1 Cross references
57 Possible Orthologues:

5-Hydroxytryptamine Receptor 3e

Ensembl ID : ENSPPRG00000004092
Gene Symbol: HTR3E
4 Cross references
38 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSPPRG00000004837
Gene Symbol: HTR4
4 Cross references
200 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSPPRG00000002723
Gene Symbol: HTR5A
4 Cross references
210 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSPPRG00000000177
Gene Symbol: HTR7
4 Cross references
219 Possible Orthologues:

60s Ribosomal Protein L26-Like

Ensembl ID : ENSPPRG00000011960
Gene Symbol: LOC109250436
3 Cross references
181 Possible Orthologues:

60s Ribosomal Protein L30-Like

Ensembl ID : ENSPPRG00000021566
Gene Symbol: LOC109271826
3 Cross references
187 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).